Company Overview
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.13.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +308.00% |
| 6 Months: | +78.74% |
| 3 Months: | +72.48% |
| 1 Month: | +51.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MBX MBX Biosciences, Inc. R2K | 56.59 | -26.08 | $2.69B | 0.00% | -26.53% | -25.73% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -10.95M | -13.31M | -16.66M | -19.61M | -26.53M | -21.80M | -23.93M | -27.27M |
| Net Income | -5.95M | -7.61M | -10.16M | -12.34M | -15.86M | -18.14M | -23.88M | -19.41M | -21.62M | -23.52M |
| Diluted EPS | - | - | -9.40 | -10.26 | -12.62 | -2.78 | -0.71 | -0.58 | -0.63 | -0.50 |
| R&D Expense | - | - | 9.07M | 11.05M | 14.40M | 16.75M | 22.41M | 17.72M | 19.27M | 18.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -35.31M | -68.19M | -98.06M |
| Net Income | -32.56M | -61.92M | -86.97M |
| Diluted EPS | -31.96 | -5.82 | -2.38 |
| R&D Expense | 28.53M | 57.41M | 79.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 84.18M | 268.54M | 385.14M |
| Total Equity | -42.60M | -72.47M | 257.44M | 369.22M |
| Cash & Equivalents | - | 30.52M | 49.35M | 75.29M |
| Total Liabilities | - | 4.29M | 11.09M | 15.92M |
| Current Liabilities | - | 3.93M | 11.05M | 15.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -31.98M | -54.68M | -79.95M |
| Investing Cash Flow | -30.93M | -160.59M | -83.70M |
| Financing Cash Flow | 69.22M | 234.10M | 189.59M |
| Capital Expenditure | -129.00K | -874.00K | -1.93M |
| Free Cash Flow | -32.11M | -55.55M | -81.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 44.9% | -24.1% | -23.6% |
| ROCE % | -44.0% | -26.5% | -26.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 13.98% | 6.65M | $393.60M |
| 2 | Orbimed Advisors LLC. | 7.64% | 3.64M | $215.25M |
| 3 | NEA Management Company, LLC | 7.59% | 3.61M | $213.87M |
| 4 | Wellington Management Group, LLP | 6.71% | 3.19M | $188.86M |
| 5 | Blackrock Inc. | 6.18% | 2.94M | $174.04M |
| 6 | FMR, LLC | 6.17% | 2.94M | $173.76M |
| 7 | Deep Track Capital, Lp | 5.79% | 2.76M | $163.17M |
| 8 | NVP Associates, LLC | 4.49% | 2.14M | $126.41M |
| 9 | Polar Capital Holdings PLC | 3.41% | 1.62M | $95.98M |
| 10 | Braidwell LP | 3.14% | 1.49M | $88.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBX
$MBX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOemc1WEs1T3MxeGlNclJLMnU5SXlzQlJmcmxheGQzQW54RlJBc1c5dnprOUU4cHRHLW1Fa2Z1VjQzejNkNjRlelpqZWxLMm5qZVVpMFVNdjJ0TmdFM296WWJJQXdESVRwZmIzRmU2VElQRXBDZGcwODVBbTdZaUZPV2tXV0F0M0xRWlVfSm…
MBX Biosciences (NASDAQ:MBX) Shares Gap Down - Should You Sell? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPTENrd3FYdEtQMzZuek8xbk9rUmRxNjVwOGVQUVVfMnVnWmxDTjl1Q0FUd09uLVQ5NXVVRHlBaDNwR2ZneFc1dGREemdRZHdRb3BFSzZkOVVnQ3pKTWR5LWs3M3cxNnRSanBLMzNYdFJ4Z2xocjJqU05mQVdLVDQ1cTd1dUZBUE9jRzZkZU…
FMR LLC's Strategic Acquisition of MBX Biosciences Inc Shares - GuruFocus
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOTEk5MW9tX2pxcnJMRGRIb3RaQ1lyaUU2NVdxSnFQZVVyTnotUFJXc190ZndjT1hDbjdRMVM0UWM2ZWR3LWxvaU1pSWR0UWItSmFtRThncDREV2lrbzlFX0stMEJoWEY2MDFGbzVyVGZOT0ZiQzN6N0I5dUp2U0VaTS1jSmhQaG5rSG1kYW…
(MBX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxONnYwZ0REN0xmZXhVc2pJaU1GQVZVb0ZvOGZ0TmZCNGRoNGZqZ25wNEpMV0hDd2VfLXJQeUZsS3ZfbXRsb20zTV9rSE8yLW44Wm92dFk4d2NqdnhXbFVBdi02LThDbVVUMlVFMjRZcm1wc1diSkIteUlxTXhLSGpqd0ktTy0tYnN6VXM1Nk…
How MBX Biosciences’ New CEO-Chairman Structure Could Reframe the MBX Investment Narrative - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNdWdrVlBxakJqVS16SjhvQU1SWUp5eUo3a0R2TTF0aHk4SXhYMHpVbGhiTWpYUjBvc092UHhGTmI2WVAteVVDQzJIYU9pTlk5Y0xCZW5sWk8xMmNiWnRfVmprVUVXS1g0ZHVWMUJOWXZjQXdfSFJkRHA1cnhQdFJORGlxLUlmZ3ZPY01jQU…
New MBX Biosciences CEO targets 3 key drug milestones by late 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQODBpSV9nZElKOWxGNmpoMHB6eHN2bWR5TjlnM1EyYWZESVZNMmRFcTBfVkQtZHJxX280WS0wR1ZBaXVSc2Vjeld0cTd5ODZIVXFFX3JySTVreXdGU3Y3cHNTZ3NNcjY1Szd5MnR5N2lLQ0d5MWlsOGlGR2oteXlKZUZqeWZCbl96YXRfWE…
MBX — Frequently Asked Questions
What is the current share price of MBX Biosciences, Inc. (MBX)?
As of 2026-07-14 21:23 PDT, MBX Biosciences, Inc. (MBX) trades at $56.59 on NasdaqGS. Its 52-week range is $9.74 to $65.71.
What is the market capitalisation of MBX?
MBX Biosciences, Inc. (MBX) has a market capitalisation of $2.69B on NasdaqGS.
What is the P/E ratio of MBX?
MBX trades at a trailing price-to-earnings (P/E) ratio of -26.08. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.86.
What is the return on equity (ROE) of MBX?
MBX has a return on equity (ROE) of -25.73%. Its return on capital employed (ROCE) is -26.53%.
Is MBX a good stock to buy?
This page provides a data-driven analysis of MBX Biosciences, Inc. (MBX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.